Cardiovascular diseases dbs testing

Dried Blood Spot Lipidomics for Cardiovascular Diseases

LipiDx AS is developing 3 different products based on the same concept but each customized to fit a specific unmet clinical need within the field of cardiovascular diseases (CVDs). Each product candidate targets a large market.

CVDs are the number one causes of death globally. More people die annually from CVDs than from any other cause. An estimated 17.3 million people died from CVD in 2008, representing 30% of all global deaths. Of these deaths, an estimated 7.3 million were due to coronary heart disease and 6.2 million due to stroke (Global atlas on cardiovascular disease prevention and control. Geneva, World Health Organization, 2011).

According to European Society of Cardiology, CVDs causes over 4 million deaths in Europe each year and 1.9 million deaths in the European Union (EU). Death rates from CHD are generally higher in Central and Eastern Europe than in Northern, Southern and Western Europe. Overall CVD is estimated to cost the EU economy almost €196 billion a year. Of the total cost of CVD in the EU, around 54% is due to health care costs, 24% due to productivity losses and 22% due to the informal care of people with CVD.

In 2010, CAD alone was projected to cost the U.S. $108.9 billion including the cost of health care services, medications, and lost productivity. According to the policy statement from the American Heart Association the CVD prevalence and costs are projected to increase substantially by 2030 (Heidenreich P et al. Circulation 2011; 123: 933-944). The projected direct and indirect cost for all CVDs is estimated to be > 1 trillion USD.